Home > Dermatology > AAD 2022 > Atopic Dermatitis: Novel Agents Enter the Stage > JAK inhibitors in AD: Setting the efficacy bar even higher

JAK inhibitors in AD: Setting the efficacy bar even higher

Presented By
Prof. Eric Simpson, Oregon Health & Science University, USA
Presented by
Eric Simpson
Medical Writer
Eric Simpson
Conference
AAD 2022
Trial
Measure Up 1; JADE Mono-1; JADE Compare; Heads Up
Systemic Janus kinase (JAK) inhibitors are currently the most potent agents for the treatment of atopic dermatitis (AD). JAK inhibitors such as upadacitinib and abrocitinib are characterised by a rapid onset of action, especially in itch reduction, and provide a safe and effective oral therapy for those who show inadequate or loss of response to biologics. “We needed something with topical steroid-like efficacy that are not steroids, we needed another option,” Prof. Eric Simpson (Oregon Health & Science University, OR, USA), emphasised in his talk on JAK inhibitors in AD [1]. Although the IL-4/IL-13 blocker dupilumab is highly efficacious in AD, not all patients respond sufficiently to treatment [2]. Besides cases of inadequate response, some patients cannot tolerate therapy with dupilumab due to side effects such as conjunctivitis, facial redness, psoriasiform dermatitis, and inflammatory arthritis [3]. In a recent retrospective study, almost 5% of pa...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on